Antimicrobial Agents Used in Intensive Care Unit
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotics Use and Antimicrobial Stewardship".
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 50327
Special Issue Editor
Interests: pharmacology; toxicology and pharmaceutics; drug-drug interaction; personalized medicine; repurposed drugs
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Antimicrobial agents constitute a fundamental part of medical treatment. Without them, the risk of bacterial or fungal infections would be intolerably high. Alexander Fleming, a Nobel Prize laureate who discovered the first antibiotic “penicillin” in 1928, warned of the stability issues associated with it that can be overcome by producing newer and better derivatives. He also warned that the sub-therapeutic usage of penicillin would cause resistant bacteria. Interestingly, Fleming’s foreshadowing has been fulfilled, as antibiotic resistance is now a modern medicine threat that is fought by clinicians all around the globe. Unfortunately, critically ill patients in intensive care units (ICUs) often suffer from pathophysiological changes that affect PK/PD target attainment and result in toxicity or under-dosing/resistance. Despite the increase in the application of therapeutic drug monitoring to adjust the dosing therapy for ICU patients, pitfalls in antimicrobial therapy are still a major concern.
This Special Issue seeks manuscripts that discuss/describe any treatment approach to overcome resistance, such as new methods for drug monitoring, discovery of new antimicrobial agents, or improvement in the stability of antimicrobial agents. In addition, manuscripts that enhance our understanding about this topic and help improve the antimicrobial therapy in ICU are welcome.
Dr. Nahed El-Najjar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- infection
- antimicrobial therapy
- toxicity
- resistance
- therapeutic drug monitoring
- personalized medicine
- intensive care units
- critically Ill patients